Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service pacemaker, ICD & CRT implantation cases in Oklahoma: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (249 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 55 | 3,154 | 24% |
| 2020 | 47 | 2,898 | 28% |
| 2021 | 44 | 2,683 | 34% |
| 2022 | 48 | 2,521 | 38% |
| 2023 | 41 | 2,398 | 42% |
| 2024 | 41 | 2,342 | 44% |
| 2025 from claims | – | 2,276 2,089–2,408 | 46% |
| 2026 forecast | – | 2,275 2,002–2,626 | 46% |
| 2027 forecast | – | 2,279 1,948–2,716 | 47% |
| 2028 forecast | – | 2,282 1,904–2,795 | 48% |
| 2029 forecast | – | 2,285 1,866–2,866 | 49% |
| 2030 forecast | – | 2,287 1,832–2,931 | 49% |
Pacemaker, leadless, ICD, S-ICD, CRT, and generator replacements. Professional codes (what the surgeon bills): CPT 33206, 33207, 33208, 33274, 33249, 33270, 33262, 33263, 33264; the hospital bills MS-DRG 242, 243, 244, 226, 227, 275, 276, 277.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 50% of the cases CMS names in Oklahoma; 22 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 39% inpatient hospital, 58% hospital outpatient, 3% surgery center.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient | Surgery center |
|---|---|---|---|
| 2026 · ~2,300 | ~900 | ~1,300 | ~66 |
| 2027 · ~2,300 | ~910 | ~1,300 | ~68 |
| 2028 · ~2,300 | ~910 | ~1,300 | ~68 |
The forecast’s cases at the projected mix.
The mix is steady: the trend moves no setting by a point or more by 2028.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Florida | 252 | 13,475−2.8%/yr | −2.8%/yr | 6.3 | 8% | 13,600 in 2030+0.2%/yr |
| Texas | 220 | 11,944−3.2%/yr | −3.2%/yr | 5.8 | 7% | 12,500 in 2030+0.7%/yr |
| Virginia | 89 | 5,169−2.2%/yr | −2.2%/yr | 5.1 | 6% | 5,360 in 2030+0.6%/yr |
| North Carolina | 100 | 4,907−3.4%/yr | −3.4%/yr | 5.2 | 0% | 5,080 in 2030+0.6%/yr |
| Tennessee | 79 | 4,585−3.7%/yr | −3.7%/yr | 6.8 | 1% | 4,450 in 2030−0.5%/yr |
| Georgia | 88 | 4,562−3.7%/yr | −3.7%/yr | 5.5 | 0% | 5,000 in 2030+1.5%/yr |
| South Carolina | 68 | 3,818−0.9%/yr | −0.9%/yr | 5.8 | 1% | 4,480 in 2030+2.7%/yr |
| Maryland | 50 | 3,380−1.5%/yr | −1.5%/yr | 3.9 | 1% | 3,330 in 2030−0.2%/yr |
| Arkansas | 40 | 2,434−5.8%/yr | −5.8%/yr | 6.7 | 0% | 2,160 in 2030−1.9%/yr |
| Alabama | 51 | 2,358−6.8%/yr | −6.8%/yr | 5.6 | 0% | 2,180 in 2030−1.3%/yr |
| Louisiana | 38 | 2,141−6.6%/yr | −6.6%/yr | 5.5 | 9% | 1,980 in 2030−1.3%/yr |
| Kentucky | 43 | 2,124−7.2%/yr | −7.2%/yr | 4.8 | 0% | 1,980 in 2030−1.2%/yr |
| Mississippi | 27 | 1,618−8.6%/yr | −8.6%/yr | 4.5 | 6% | 1,500 in 2030−1.3%/yr |
| West Virginia | 18 | 1,108−1.5%/yr | −1.5%/yr | 5.5 | 0% | 1,020 in 2030−1.4%/yr |
| Delaware | 13 | 724−4.8%/yr | −4.8%/yr | 4.3 | 0% | 790 in 2030+1.4%/yr |
| District of Columbia | 10 | 494−2.1%/yr | −2.1%/yr | 8.1 | 0% | 510 in 2030+0.4%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| LAA occlusion & loop recorders | 50 | 1,926+8.2%/yr | +8.2%/yr | 3.61.0× | 8% | 3,560 in 2030+11%/yr |
| EP ablation | 23 | 1,684+4.1%/yr | +4.1%/yr | 3.00.8× | 0% | 2,960 in 2030+9.9%/yr |
Pacemaker, ICD & CRT implantation in every state, and its device makers · Every procedure market in Oklahoma · Every state · Compare with Florida
Cvrx leads with 38% of company spending on these surgeons in 2025, +19 pts on 2024.
In 2025, 8 companies reported engagement with Oklahoma’s surgeons worth $136K in consulting, speaking, meals and travel tied to these products, about $3,319 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 339 clearances and approvals in the category, 3 recalled product lines (2 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.